Cronos Group CRON
$3.04 −$0.04 (-1.30%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.06 +0.66%
Open$3.05
Prev close$3.08
Day range$3.02 – $3.12
Volume1.92M
Market cap$1.11B
P/E (TTM)19.0
Dividend yield–
CRON Stock News
Headlines matching Cronos Group or the CRON ticker, most recent first.
- Analysts Offer Insights on Healthcare Companies: Community Health (CYH) and Cronos Group (CRON)
- TD Cowen Maintains Cronos Group(CRON.US) With Buy Rating, Raises Target Price to $4.94 Positive
- Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Cronos Group (CRON)
- Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Cronos Group (CRON) and Boston Scientific (BSX)
- Cronos Group Announces Extension of Shr Repurchase Program to the Toronto Stk Exchange CRON.T
- Citron Founder, a Short-Selling Giant, on Trial: CEO of Cronos Group (CRON.US) Cross-Examined, Unveiling Details of Alleged 'Short-and-Smear' Scheme
- Bernstein Initiates Cronos Group(CRON.US) With Hold Rating
- TD Cowen Maintains Cronos Group(CRON.US) With Buy Rating, Raises Target Price to $4.02 Positive
- Earnings Flash (CRON) Cronos Group Inc. Reports Q1 Revenue $45.2M, Vs. FactSet Est of $42.2M
- TD Cowen Initiates Cronos Group(CRON.US) With Buy Rating, Announces Target Price $3.28
- Cronos Completes Acquisition Of CanAdelaar, Europe's Largest Adult-Use Cannabis Company CRON.T
- CCORF Initiates Cronos Group(CRON.US) With Buy Rating, Announces Target Price $3.14
- Cronos Group (CRON) Gets a Hold From Bernstein
- Roth MKM Initiates Cronos Group(CRON.US) With Buy Rating
- BofA Securities Maintains Cronos Group(CRON.US) With Sell Rating, Cuts Target Price to $1.65 Negative
No comments yet — be the first to weigh in on CRON.
Sign in to join the discussion.